Literature DB >> 30312578

A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.

Tiffany A Chen1, Ryan A Shields1, Zachary H Bodnar1, Natalia F Callaway1, Ira H Schachar1, Darius M Moshfeghi2.   

Abstract

PURPOSE: To describe an improved understanding of the regression patterns following off-label intravitreal bevacizumab (IVB) treatment for retinopathy of prematurity (ROP).
DESIGN: Retrospective cohort study.
METHODS: All infants treated with IVB for type 1 ROP at a single institution from June 2013 to March 2018 were retrospectively reviewed and the amount of retinal nonperfusion on fluorescein angiogram was calculated.
RESULTS: In the 92 eyes of 46 patients analyzed, only 3 eyes (3.3%) reached full vascular maturity. Of the 89 eyes not reaching maturity, 39 eyes (43.8%) had vascular arrest alone (VAA), 34 eyes (38.2%) had vascular arrest with persistent tortuosity (VAT), and 16 eyes (18.0%) had ROP reactivation. Those eyes that reactivated were more likely to be initially classified as having aggressive posterior ROP (P = .004) and of Asian ethnicity (P = .008). There were greater areas of ischemia in eyes with reactivation as compared to VAT and VAA (112.1 mm2 vs 72.5 mm2 vs 56.6 mm2, respectively, P = .007). Younger gestational age at birth was found to be an independent predictor of persistent tortuosity (VAT vs VAA) in a logistic regression model.
CONCLUSIONS: Incomplete vascularization following IVB is very common and is associated with a younger gestational age at birth, Asian ethnicity, and aggressive posterior ROP. The presence of tortuosity following IVB may be indicative of persistently elevated vascular endothelial growth factor levels and an early indicator of potential reactivation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30312578     DOI: 10.1016/j.ajo.2018.09.039

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.

Authors:  Sasha A Mansukhani; Amy K Hutchinson; Rebecca Neustein; Joseph Schertzer; John C Allen; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2019-01-31

2.  Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.

Authors:  Amir Sternfeld; Safa Rahmani; Jennifer L Rossen; David L Zhang; Yuping D Li; Victor L Quan; Russell Huang; Hawke H Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-12-01       Impact factor: 3.117

Review 3.  Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Authors:  Nita G Valikodath; Michael F Chiang; R V Paul Chan
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

4.  Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.

Authors:  Fengjie Xia; Jiao Lyu; Jie Peng; Peiquan Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-19       Impact factor: 3.535

5.  The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.

Authors:  Ayşegül Çömez; Yalçın Karaküçük; Mehmet Cüneyt Özmen; Pelin Çelemler; Oğuzhan Saygılı
Journal:  Eye (Lond)       Date:  2021-01-29       Impact factor: 3.775

Review 6.  80 Years of vision: preventing blindness from retinopathy of prematurity.

Authors:  Edward H Wood; Emmanuel Y Chang; Kinley Beck; Brandon R Hadfield; Amy R Quinn; Clio Armitage Harper
Journal:  J Perinatol       Date:  2021-03-05       Impact factor: 3.225

Review 7.  Cataract in retinopathy of prematurity - A review.

Authors:  Sudarshan Khokhar; Abhidnya Surve; Saurabh Verma; Shorya Azad; Parijat Chandra; Chirakshi Dhull; Rajpal Vohra
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

8.  Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.

Authors:  Kaveh Fadakar; Mohammadreza Mehrabi Bahar; Hamid Riazi-Esfahani; Afsaneh Azarkish; Afsar Dastjani Farahani; Mostafa Heidari; Fatemeh Bazvand
Journal:  Int Ophthalmol       Date:  2022-01-20       Impact factor: 2.029

9.  Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity.

Authors:  Ramak Roohipoor; Hamidreza Torabi; Reza Karkhaneh; Mohammad Riazi-Eafahani
Journal:  J Curr Ophthalmol       Date:  2018-11-09

10.  Modeling absolute zone size in retinopathy of prematurity in relation to axial length.

Authors:  Sean K Wang; Edward Korot; Moosa Zaidi; Marco H Ji; Ahmad Al-Moujahed; Natalia F Callaway; Jochen Kumm; Darius M Moshfeghi
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.